Everything tagged "insiders" across the TickerSpark archives.
Netskope looks more interesting as an AI-security platform story than as just another SASE stock, and the recent insider buying gives that shift real weight. The losses are still ugly, but 28%-29% top-line and ARR growth plus a rapid AI product cadence make the reset look more like a re-rating setup than a broken thesis.
Jefferies just got a board-level vote of confidence that is too large to dismiss as noise. A roughly $318.7 million Sumitomo purchase landed right after a quarter with record equities revenue and a sharp rebound in investment banking.
The market is obsessing over Gloo's fresh share sale and missing the more important signal: management is still guiding to EBITDA breakeven in Q3 and profitability in Q4 while insiders have lined up at least $6.0 million for the deal. At 0.50x sales after a 47.1% YTD collapse, this looks more like a stressed setup around dilution than a broken operating story.
Netskope’s story is not broken just because ARR growth has cooled. The market is obsessing over the post-IPO reset while management is still expanding distribution and embedding the platform into the enterprise AI stack.
Vicor’s selloff looks like an insider-optics panic, not a collapse in the AI power thesis. The business is still putting up beats, strong margins, and a raised Q2 outlook that says demand is alive.
Polestar did not lose its entire business when the U.S. connected-vehicle ruling hit, but it did lose the clean EV-turnaround narrative. PSNY now looks like a Europe-first restructuring story backed by insider buying, fresh capital support, and a market that still has to decide whether survival is enough.
Nuvectis took a painful dilution hit, but this is one of the rare biotech raises that actually improves the story. A $100 million financing landed right after a pipeline expansion deal, turning NVCT from a cash-tight single-asset bet into a funded three-program clinical setup.
Wallbox still looks ugly on the income statement, but the balance-sheet story changed more than the market seems willing to admit. A court-approved restructuring and $7.5 million of insider buying make WBX look less like a survival trade and more like an early recap turnaround.
CarMax looks like a turnaround stock, not a broken retailer, and the recent insider buying makes that distinction matter. Management is putting real money behind a post-earnings repair story just as revenue, unit trends, and cost discipline start to move the right way.
Liberty Latin America looks more interesting now because the insider alignment around its preferred-stock rollout is unusually large and unusually timely. With Q1 operations running ahead of internal expectations and the stock still trading at just 0.48x sales, we think the market is still behind the turn.
Crane NXT’s post-earnings drop looks more like an overreaction than a broken thesis. Management kept 2026 EPS guidance intact, currency demand still looks solid, and the CEO just put about $1.01 million of personal money into CXT stock.
Mission Produce looks like a commodity produce stock on the surface, but the story changed fast. The Calavo acquisition, a new $100 million buyback, and heavy insider buying make AVO look more like a scale-and-capital-allocation setup than a pure avocado price trade.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime